Satvik Ramakrishna, MD
Cardiovascular Disease · San Francisco, CANPI 1881004810
Payments from drug & device makers
Across 25 payments — averaging $135.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abbott$718
- Philips North America LLC$550
- Lantheus Medical Imaging, Inc.$54
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$42
- Astellas Pharma US Inc$24
What the payments were for
- Travel & lodging$2,60577%
- Food & beverage$78223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 8 | $1,999 |
| Abbott | 7 | $718 |
| Philips North America LLC | 5 | $550 |
| Lantheus Medical Imaging, Inc. | 2 | $54 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Astellas Pharma US Inc | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVOQUE$1,731
- TRICLIP$621
- (9525) Intracardiac Und$482
How this compares
$3,387 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $76,739 |
| JardianceEmpagliflozin | 21 | $36,565 |
| FarxigaDapagliflozin Propanediol | 15 | $18,772 |
| EntrestoSacubitril/Valsartan | 11 | $15,647 |
| Repatha SureclickEvolocumab | 12 | $6,432 |
| Metoprolol Succinate | 60 | $1,288 |
| Torsemide | 13 | $871 |
| Rosuvastatin Calcium | 51 | $563 |
| Atorvastatin Calcium | 51 | $454 |
| Carvedilol | 54 | $448 |
| Ezetimibe | 24 | $419 |
| Spironolactone | 52 | $399 |
| Olmesartan Medoxomil | 20 | $286 |
| Amlodipine Besylate | 28 | $223 |
| Lisinopril | 25 | $208 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in San Francisco
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Theodore AbrahamSan Francisco$1.6M
- Jonathan ZaroffSan Francisco$791K
- Philip SagerSan Francisco$675K
- Javid MoslehiSan Francisco$651K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.